{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:29:09Z","timestamp":1794209349308,"version":"4.8.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the clinical and radiological features, as well as outcomes following glucocorticoid therapy and recurrence in adults suffering from cortical encephalitis associated with myelin oligodendrocyte glycoprotein (MOG) antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical information of nine adult patients suffering from cortical encephalitis associated with MOG antibody admitted to the Affiliated Brain Hospital of Nanjing Medical University from 2020 to 2022 was systematically reviewed. The clinical symptoms, laboratory data, imaging results, outcomes following glucocorticoid therapy and recurrence were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>A total of 9 patients positive for MOG antibody and suffering from cortical encephalitis were included in our study (55.6% men, median age 29\u2009years, 15\u201357\u2009years). The most common clinical symptoms included headache (77.8%), fever (66.7%), and generalized seizures (55.6%). Some patients also experienced limb shaking (22.2%), leg numbness (22.2%), transient motor aphasia (11.1%), and vision loss (11.1%). The main features of cerebrospinal fluid () examination were increased intracranial pressure, pleocytosis, and elevated cerebrospinal fluid (CSF) protein. In addition, N-methyl-D-aspartate receptor (NMDAR) and MOG antibodies were found in the CSF of 3 patients, and NMDAR, MOG, and glial fibrillary acidic protein antibodies were found in the CSF of 1 patient. All patients were subjected to magnetic resonance imaging (MRI) and the images of eight of them showed T2 and\/flair image hyperintense lesions, three showed meningeal or lesion enhancement and four showed white matter lesions, which were mostly located in the midline structures (75%). All patients received glucocorticoid therapy in the acute phase and in remission, and eight of them received an intravenous high dose of methylprednisolone, including one patient who received a simultaneous immunoglobulin therapy. One patient was treated with low-dose prednisolone tablets. Seven (77.8%) patients were wholly recovered at discharge, and 2 (22.2%) patients were left with slight symptoms. During the median 9-month follow-up (range: 2\u201336\u2009months), 2 (22.2%) patients developed recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The clinical manifestations of adult MOG antibody-associated cortical encephalitis were significantly different from those of the typical MOG antibody-associated disease (MOGAD). Patients in the acute phase of the disease were prone to show signs similar to central nervous system infection, requiring clinicians to have the ability to recognize the disease to avoid misdiagnosis. In addition, seizures were common in MOG antibody-related encephalitis, and the type of seizures was age-related. Brain MRI results showed that the distribution of cerebral cortex lesions was closely related to the classification of cortical encephalitis. Based on the patient\u2019s response to the treatment, glucocorticoid therapy was effective against MOG antibody-associated cortical encephalitis, which is consistent with the treatment response and clinical prognosis of MOGAD. Therefore, our opinion was that MOG antibody might be the \u201cresponsible antibody\u201d in MOG antibody-associated cortical encephalitis, although further studies are needed to confirm this hypothesis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2022.1076361","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:46:14Z","timestamp":1672850774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical characteristic of myelin oligodendrocyte glycoprotein antibody associated cortical encephalitis in adults and outcomes following glucocorticoid therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuqing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.5692\/clinicalneurol.cn-001224","article-title":"Cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein (MOG) antibody","volume":"58","author":"Adachi","year":"2018","journal-title":"Rinsho Shinkeigaku"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ijms22010100","article-title":"Myelin Oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management","volume":"22","author":"Ambrosius","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1573406413666170906123204","article-title":"Myelin Oligodendrocyte glycoprotein and multiple sclerosis","volume":"14","author":"Androutsou","year":"2018","journal-title":"Med. Chem."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J. Neurol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"di Pauli","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"711376","DOI":"10.3389\/fneur.2021.711376","article-title":"Clinical features of coexisting anti-NMDAR and MOG antibody-associated encephalitis: a systematic review and meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Neurol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"600169","DOI":"10.3389\/fneur.2020.600169","article-title":"Clinical and radiological features of adult onset bilateral medial frontal cerebral cortical encephalitis with anti-myelin Oligodendrocyte glycoprotein antibody","volume":"11","author":"Fujimori","year":"","journal-title":"Front. Neurol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"577322","DOI":"10.1016\/j.jneuroim.2020.577322","article-title":"Unilateral chronic pulsatile headache as the single manifestation of anti-MOG antibody-associated unilateral cerebral cortical encephalitis","volume":"346","author":"Fujimori","year":"","journal-title":"J. Neuroimmunol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"577002","DOI":"10.1016\/j.jneuroim.2019.577002","article-title":"Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behcet's disease","volume":"334","author":"Fujimori","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jns.2018.06.028","article-title":"The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: a case report","volume":"392","author":"Ikeda","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"103216","DOI":"10.1016\/j.msard.2021.103216","article-title":"Treatment of MOG-IgG associated disease in paediatric patients: a systematic review","volume":"56","author":"Klein da Costa","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1191\/1352458506ms1290oa","article-title":"Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions","volume":"12","author":"Merkler","year":"2006","journal-title":"Mult. Scler."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1212\/NXI.0000000000000538","article-title":"Anti-MOG encephalitis mimicking small vessel CNS vasculitis","volume":"6","author":"Patterson","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1212\/WNL.0000000000002825","article-title":"Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.3389\/fimmu.2018.02802","article-title":"Autoimmune glial Fibrillary acidic protein Astrocytopathy: a review of the literature","volume":"9","author":"Shan","year":"2018","journal-title":"Front. Immunol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/bpa.12292","article-title":"A new targeted model of experimental autoimmune encephalomyelitis in the common marmoset","volume":"26","author":"Stassart","year":"2016","journal-title":"Brain Pathol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"577987","DOI":"10.1016\/j.jneuroim.2022.577987","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: presentation and outcomes of adults at a single center","volume":"373","author":"Sutton","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/jdn.10106","article-title":"MOG antibody-positive cerebral cortical encephalitis: two case reports and literature review","volume":"81","author":"Tian","year":"2021","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.autrev.2013.10.016","article-title":"Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system","volume":"13","author":"van Coevorden-Hameete","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"582768","DOI":"10.3389\/fimmu.2021.582768","article-title":"The clinical features of FLAIR-Hyperintense lesions in anti-MOG antibody associated cerebral cortical encephalitis with seizures: case reports and literature review","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"103727","DOI":"10.1016\/j.msard.2022.103727","article-title":"Clinical analysis of adult MOG antibody-associated cortical encephalitis","volume":"60","author":"Yao","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fneur.2019.00415","article-title":"Seizure and myelin Oligodendrocyte glycoprotein antibody-associated encephalomyelitis in a retrospective cohort of Chinese patients","volume":"10","author":"Zhong","year":"2019","journal-title":"Front. Neurol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.msard.2017.09.023","article-title":"Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies","volume":"18","author":"Zhou","year":"2017","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.1076361\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:46:16Z","timestamp":1672850776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.1076361\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":39,"alternative-id":["10.3389\/fnagi.2022.1076361"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.1076361","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1076361"}}